TW202233235A - 艾薩妥昔單抗用於治療多發性骨髓瘤的用途 - Google Patents

艾薩妥昔單抗用於治療多發性骨髓瘤的用途 Download PDF

Info

Publication number
TW202233235A
TW202233235A TW110140853A TW110140853A TW202233235A TW 202233235 A TW202233235 A TW 202233235A TW 110140853 A TW110140853 A TW 110140853A TW 110140853 A TW110140853 A TW 110140853A TW 202233235 A TW202233235 A TW 202233235A
Authority
TW
Taiwan
Prior art keywords
month
antibody
serum
protein
dose
Prior art date
Application number
TW110140853A
Other languages
English (en)
Chinese (zh)
Inventor
多蘿西 瑟米昂德
懷足 蔡
海爾吉 范德維爾德
福萊特 克里斯汀 維拉特
Original Assignee
美商賽諾菲 安萬特美國有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽諾菲 安萬特美國有限責任公司 filed Critical 美商賽諾菲 安萬特美國有限責任公司
Publication of TW202233235A publication Critical patent/TW202233235A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
TW110140853A 2020-11-03 2021-11-02 艾薩妥昔單抗用於治療多發性骨髓瘤的用途 TW202233235A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US63/109,305 2020-11-03
US202163239108P 2021-08-31 2021-08-31
US63/239,108 2021-08-31

Publications (1)

Publication Number Publication Date
TW202233235A true TW202233235A (zh) 2022-09-01

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110140853A TW202233235A (zh) 2020-11-03 2021-11-02 艾薩妥昔單抗用於治療多發性骨髓瘤的用途

Country Status (8)

Country Link
US (1) US20220135696A1 (https=)
EP (1) EP4240416A1 (https=)
JP (1) JP2023550311A (https=)
AU (1) AU2021376374A1 (https=)
CA (1) CA3197381A1 (https=)
IL (1) IL302640A (https=)
TW (1) TW202233235A (https=)
WO (1) WO2022099257A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
KR20210006321A (ko) * 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020212912A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
EP3969004A1 (en) * 2019-05-14 2022-03-23 Sanofi Methods of administering anti-cd38 antibody to treat multiple myeloma

Also Published As

Publication number Publication date
IL302640A (en) 2023-07-01
EP4240416A1 (en) 2023-09-13
WO2022099257A1 (en) 2022-05-12
CA3197381A1 (en) 2022-05-12
JP2023550311A (ja) 2023-12-01
US20220135696A1 (en) 2022-05-05
AU2021376374A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7712206B2 (ja) 多発性骨髄腫の処置方法
KR101745230B1 (ko) Pan-ELR+ CXC 케모카인 항체
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
US20240148894A1 (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
CN120424218A (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
JP2023521228A (ja) 癌の併用療法
TW202233235A (zh) 艾薩妥昔單抗用於治療多發性骨髓瘤的用途
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
CN109641053A (zh) 给药方案
EP3908610A1 (en) Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
CA3048198A1 (en) Methods of treating multiple myeloma
CN116761627A (zh) 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途
RU2838203C2 (ru) Способы лечения множественной миеломы
WO2025109518A1 (en) Methods for treatment of myeloproliferative neoplasms
TW202610683A (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途